Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Last year, Scynexis launched Brexafemme (ibrexafungerp), indicated ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the developer of the treatment, Scynexis, has resumed a phase 3 study in another use.

Scynexis hit the market eight months ago with Brexafemme, a long-awaited upgrade in the treatment of vaginal yeast infection. Now, the New Jersey drugmaker is delivering data for the drug that may ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. On Tuesday, June 1 st, the Food and Drug Administration on Tuesday ...

A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured patients in the U.S. JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ...

(RTTNews) - Scynexis Inc. (SCYX) said that the U.S. Food and Drug Administration has approved Brexafemme or ibrexafungerp tablets, for oral use in patients with vulvovaginal candidiasis or VVC, also ...

SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, ...

Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, ...

Biogen’s Aduhelm (aducanumab) has received accelerated approval for treating patients with Alzheimer’s disease, making it the first new treatment for the disease since 2003. The human monoclonal ...

Credit: Scynexis. Brexafemme is a triterpenoid antifungal. Brexafemme ® (ibrexafungerp tablets) is now available for the treatment of vulvovaginal candidiasis in adult and postmenarchal pediatric ...

JERSEY CITY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...